Antiproteinuric effect of calcium antagonists on puromycin-induced experimental nephrosis.
Calcium antagonists have a potential for beneficial effects on kidney function unrelated to their antihypertensive action. In this study we have investigated the efficacy of calcium antagonists compounds (verapamil, nifedipine and diltiazem) on reversible acute renal insufficiency, proteinuria and interstitial nephritis induced by the puromycin ammonucleoside (PAN). An increase in blood pressure (BP) was detected on day 14, with no statistical differences in the response to calcium antagonists. Serum creatinine concentration increased to 1.2 mg/dL on day 7 after PAN and decreased to 0.7 mg/dL at 14 days, calcium antagonists shortened the time required to reach baseline or control levels. Calcium antagonists also reduced proteinuria in the PAN-treated animals, in both day 7 and day 14. Differential effects of the antagonists were observed. Verapamil caused a greater reduction (p < 0.01) in proteinuria than nifedipine or diltiazem in day 7. Moreover, verapamil (p < 0.01) and nifedipine (p < 0.01) reduced the total number of interstitial infiltrating leukocytes from 690 to 120 and 425 positive cells/20 high power fields (x63) respectively, by contrast, diltiazem had no effect. We conclude that in this model of PAN nephropathy verapamil is more effective in reducing both proteinuria and the severity of acute interstitial nephritis than either nifedipine or diltiazem. The possible clinical implications of these results remain to be elucidated.
Martin
A
A
Department of Pathology, Hospital Ramon y Cajal, University of Alcalá, Madrid, Spain.
Cuevas
B
B
Escudero
E
E
Nieto
E
E
Cuevas
P
P
Pascual
J
J
Ortuño
J
J
Orte
L
L
Mampaso
F
F
D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D009401:Nephrosis / Q000188:drug therapy*; D011691:Puromycin; D051381:Rats; D017207:Rats, Sprague-Dawley
D002121:Calcium Channel Blockers; D011691:Puromycin